Atavistik Bio
Atavistik Bio is seeking a Principal Scientist to lead biology and translational research in hematologic disorders. The role involves working with in vivo models and biomarkers, collaborating across teams, and supporting drug development efforts in a fast-paced biotech environment.
Headquarters
Cambridge, Massachusetts, United States
Company Size
11-50 employees
Founded
2021
Atavistik Bio is a clinical-stage biotechnology company focused on harnessing the power of allostery to develop transformative medicines. The company's approach enables selective modulation of disease-causing proteins, with lead asset ATV-1601, an oral allosteric AKT1-selective inhibitor being developed for Hereditary Hemorrhagic Telangiectasia (HHT), and a JAK2V617F mutant-selective inhibitor program for myeloproliferative neoplasms. Atavistik Bio aims to deliver best-in-class allosteric therapeutics to address serious unmet patient needs.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Atavistik Bio.
Atavistik Bio Raises $120 Million Series B Financing to
Dec 18, 2025
Senior Scientist (Bioscience – Translational Biology)
Cancer Research UK Jersey
Principal Scientist – Cardiometabolic Diseases/Obesity Research
Amgen
Associate Scientist, Translational Biology
Septerna
Sr. Principal Scientist - Translational Muscle Biology
City of Pierre, South Dakota
Senior Principal Scientist - Translational Muscle Biology
UCB
Senior Principal Scientist - Translational Muscle Biology
UCB